A Phase II Study of Nivolumab or Ipilimumab with or without Azacitidine for Patients with Myelodysplastic Syndrome (MDS)

Conclusion: The incorporation of ICPI is feasible in MDS. These agents have significant activity as single agents and in combination in MDS with an acceptable toxicity profile and significant response and survival outcomes, particularly with ipilimumab. Further randomized studies are needed.DisclosuresSasaki: Otsuka Pharmaceutical: Honoraria. Daver: Novartis: Research Funding; ARIAD: Research Funding; Karyopharm: Consultancy; Kiromic: Research Funding; Sunesis: Consultancy; Otsuka: Consultancy; Incyte: Consultancy; BMS: Research Funding; Daiichi-Sankyo: Research Funding; Alexion: Consultancy; Pfizer: Research Funding; Incyte: Research Funding; Novartis: Consultancy; ImmunoGen: Consultancy; Pfizer: Consultancy; Sunesis: Research Funding; Karyopharm: Research Funding. DiNardo: Medimmune: Honoraria; Karyopharm: Honoraria; Celgene: Honoraria; Abbvie: Honoraria; Agios: Consultancy; Bayer: Honoraria. Ravandi: Xencor: Research Funding; Bristol-Myers Squibb: Research Funding; Astellas Pharmaceuticals: Consultancy, Honoraria; Sunesis: Honoraria; Seattle Genetics: Research Funding; Macrogenix: Honoraria, Research Funding; Sunesis: Honoraria; Macrogenix: Honoraria, Research Funding; Orsenix: Honoraria; Jazz: Honoraria; Abbvie: Research Funding; Orsenix: Honoraria; Seattle Genetics: Research Funding; Amgen: Honoraria, Research Funding, Speakers Bureau; Astellas Pharmaceuticals: Consultancy, Honoraria; Jazz: Honoraria; Amgen: Honoraria, Research Funding, Speakers Bureau; Abbvie: Research ...

Source: Blood - November 21, 2018 Category: Hematology Authors: Garcia-Manero, G., Sasaki, K., Montalban-Bravo, G., Daver, N. G., Jabbour, E. J., Alvarado, Y., DiNardo, C. D., Ravandi, F., Borthakur, G., Bose, P., Pemmaraju, N., Naqvi, K., Cortes, J. E., Kadia, T. M., Konopleva, M. Y., Colla, S., Yang, H., Rausch, C. Tags: 637. Myelodysplastic Syndromes-Clinical Studies: Novel Therapeutics II Source Type: research